Avita is a long term growth story, yet I see a big pot of gold at the end of the rainbow, realistically. The Recell product is simple, cost-effective, and extremely beneficial to humanity. The expanded market opportunity is promising, and management is talented. Again, capturing the same market share with soft tissue and vitiligo as Avita has with burns will lead to approximately $1 billion revenue per year ($10 million quarterly X 25 times target market X 4 quarters). If 50% of that is FCF with a conservative PE of 10, we get a $5 billion market cap. This is hypothetical but conservatively realistic based on historical sales and market share figures while considering an overall market opportunity increase of 25 times. What a growth story!
Media, page-42
-
- There are more pages in this discussion • 195 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.12 |
Change
-0.050(1.58%) |
Mkt cap ! $219.7M | |||
| Open | High | Low | Value | Volume |
| $3.15 | $3.15 | $3.09 | $174.0K | 55.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 221 | $3.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.13 | 399 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVH (ASX) Chart |